Shionogi Europe is a new healthcare company, launched approximately 130 years after the organisation was founded (1878) by Gisaburo Shiono SR. in Doshomachi, Osaka, Japan. The company has grown to become a major research-driven pharmaceutical company dedicated to placing the highest value on patient care.
We are guided by a simple but powerful principle: follow the needs of the patient and the community that surrounds them. This means ensuring that the real-life challenges patients face everyday remain the primary purpose behind R&D, which we believe is a more encouraging way to create clinically-meaningful therapies.
Products and services
We are a research-led organisation, defined by a distinct openness and close partnership approach to creating vaccines and medicines spanning pain, infectious diseases, metabolic disorders, women’s health and oncology.
Our development approach goes hand in hand with the collaborative drug discovery process at the heart of Shionogi. We have an impressive track record of fostering long-term industry partnerships built on trust and a mutual ambition to develop innovative medicines that address unmet medical needs. In 1998 Shionogi licensed one of its new molecules, which later became Crestor (rosuvastatin) to AstraZeneca and still markets this product in Japan today. Other important discoveries include Tivicay and Triumeq, new anti-HIV drugs now marketed by ViiV Healthcare.
Contact
Address: 33 Kingsway, London WC2B 6UF
Tel: +44-203-053-4200
Web: www.shionogi.eu
Novartis Italy’s Georg Schroeckenfuchs discusses the impact of the company’s global restructuring on the Italian affiliate, the significance of local manufacturing, new products, and how the Novartis has managed to…
Giuseppe Martini, President at the National Technological Cluster: Advanced Life Sciences in Italy (ALISEI) discusses the founding of the ALISEI cluster, its main missions and how it helps Italy to…
Elena Tremoli, Scientific Director at Centro Cardiologico Monzino, explains the importance of both applied and cardiovascular research in Italy, and how prevention in this area will be key in the…
Eugenio Aringhieri discusses Dompé’s shift in strategy towards opthalmology, instilling an innovation mindset, and broadening the company’s international horizons. Since we last interviewed you in 2009 a lot has happened:…
Pier Mannuccio Mannucci, Scientific Director of the Policlinico Foundation, describes some of the challenges the scientific community currently faces in Italy and what actions need to be taken to overcome…
The President and MD of Abiogen Pharma discusses his family company’s recent milestones, the reasons for persisting with local manufacturing, and the benefits of international partnerships. You created Abiogen back…
Ferring Italy’s CEO discusses the affiliate’s successful management strategy, new products, new partnerships, and the potential of the Italian market. When we last interviewed you in 2009, you were focused…
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Galderma Italy was a founding European affiliate for the company and has seen incredible growth in the past two decades. Managing Director Bernat Albinyana discusses the affiliate’s performance, its business…
Dr. Ermano Buratti, General Manager for Astellas Pharma in Italy, discusses the company’s evolution as it enters its second decade, the importance of partnering with the government on reimbursement, the…
In 2008 Focus Reports interviewed Mr. Federico Seghi Recli as he prepared to transform Molteni Farmaceutici into an International specialty pharma company. Today we catch up on the progress, investments…
The General Manager for Eli Lilly Italy, discusses how the company’s continuous commitment to Italy has benefited the organization, the promise the country holds if certain barriers can be overcome, and how Lilly’s…
See our Cookie Privacy Policy Here
